Alpha Cognition: Alzheimer’s Treatment with Minimal Side Effects

Therapeutic option for Alzheimer’s patients

Alpha Cognition Inc. is a privately held biopharmaceutical company focused on the development of novel therapies to treat diseases of the brain and spinal cord. They embarked on research programs to find alternative ways of treating Alzheimer’s disease and Amyotrophic Lateral Sclerosis (ALS), also called Lou Gehrig’s Disease. To date, both are very serious conditions that have major unmet medical needs.

Alzheimer’s disease is a chronic neurodegenerative disease that is the cause of 60–70% of cases of dementia. Alzheimer’s impacts millions of people worldwide. Currently approved drugs treat only symptoms and each of them cause significant gastro-intestinal side effects.

One of these drugs, Galantamine, is reported to enhance cognition and delay the progression of symptoms of Alzheimer’s disease. However, few patients can tolerate the high doses required for long periods of time.

Alpha Cognition has created Alpha-1062. This is a patented new therapy whose metabolites are identical to those of Galantamine but remain inert until entering the circularity system, with minimal side effects.

More about Alpha-1062

Alpha-1062 is designed as a new generation acetylcholine esterase inhibitor. Further, it has minimal gastro-intestinal side effects and offers new routes of administration. Alpha-1062 is a patented new chemical entity (NCE) that passes into circulation with little or no side effects, then metabolizes into galantamine where it acts as a recognized and potent acetylcholine esterase inhibitor. Dosages include tablet and nasal spray that allow immediate efficacious dosing (no titration), significantly reduced side effects (which may result in improved adherence/compliance), with statistically significant clinical evidence of improved mental acuity and safety when compared to other approved AcEI therapeutics.

The FDA has reviewed and agreed to a regulatory strategy requiring only a single pivotal trial to achieve registration. Studies are expected to be completed in 2021, with US and Japanese NDA submissions to follow.

Alpha Cognition is searching for commercialization partners to market this therapeutic option for Alzheimer’s patients.

For more information on Alpha Cognition Inc. please visit their website at